137 Days Remain
As of June 28, 2026, the federal hemp compliance deadline of November 12 is approximately 137 days away. For brands and manufacturers who have completed the foundational work — qualified suppliers, HPLC-based testing, documentation systems, and reformulation of non-compliant SKUs — this is a period of confirmation and refinement. For those who are still in the middle of compliance work, or who have not yet started, these are the most consequential weeks of the transition.
This action plan is written for the latter group: organizations that are partially or not yet compliant and need a structured path through the final stretch. It is organized into three phases — a 30-day foundation phase, a 60-day execution phase, and a 30-day confirmation phase — timed to reach readiness by October 31, giving two weeks of buffer before November 12.
Phase 1: Foundation (Days 1–30 — July 1–31, 2026)
The first 30 days are about establishing the documentation and organizational foundation on which the rest of the compliance sprint depends.
Week 1–2: Complete Your Compliance Gap Assessment
You cannot fix what you haven’t measured. Start with a systematic audit of your current state:
Product inventory review: List every SKU you currently sell or plan to sell after November 12. For each one, identify:
- Cannabinoid content (per serving and per container)
- Total THC calculation: delta-9 THC + (THCA × 0.877) — per container
- Whether total THC per container is at or below 0.4 mg
- Whether the formulation contains any synthetic cannabinoids (delta-8 from isomerization, HHC, THC-O, etc.)
Supplier documentation review: For each active hemp ingredient supplier:
- Is testing from a DEA-registered, ISO 17025-accredited laboratory?
- Are COAs HPLC-based with separate THCA and delta-9 THC reporting?
- Is chain of custody documentation complete?
- Is a GMP certification current and on file?
- Is a quality agreement in place?
Output: A gap list — every product that needs reformulation, every supplier with documentation gaps, every testing protocol that needs updating.
Week 3–4: Prioritize and Assign
With your gap list in hand, prioritize:
- Which product gaps represent the highest revenue risk if unresolved?
- Which supplier documentation gaps are most urgent (DEA lab qualification is harder to work around than a missing allergen statement)?
- Who in your organization is responsible for each gap, and by what date will it be resolved?
Create a tracking document that assigns each gap to an owner with a completion date. Review it weekly.
Phase 2: Execution (Days 31–90 — August 1–September 29, 2026)
Phase 2 is the heavy lifting: reformulating non-compliant products, transitioning suppliers, completing documentation, and building the compliance infrastructure that will carry you through November 12 and beyond.
Product Reformulation
For products that exceed the 0.4 mg total THC per container limit:
Option 1: Reduce cannabinoid concentration. Reformulate to use lower-THC extract or reduce the quantity of extract per serving/container. This is often the fastest path to compliance but may require label changes and product notification to retailers.
Option 2: Switch extract format. Products using full-spectrum extract may meet compliance thresholds more easily with broad-spectrum (THC-removed) or isolate-based formulations. Trade-off: the product's cannabinoid profile changes.
Option 3: Change serving size. If the total THC is being calculated from a serving size that could be reduced, reducing the serving size may bring per-container totals into compliance. This requires careful label math and regulatory review.
Option 4: Discontinue. For products that cannot be reformulated to compliance economically, discontinuation before November 12 is better than carrying non-compliant product into the enforcement period.
For products containing synthetic cannabinoids: discontinuation is the only path. There is no reformulation route that keeps delta-8 from isomerization, HHC, or THC-O in a compliant product after November 12.
Supplier Transitions
If you have active suppliers whose documentation doesn’t meet the standard:
- Begin qualification of replacement suppliers immediately. Supplier qualification typically takes 4–12 weeks including sampling, testing, documentation review, and trial production.
- Communicate clearly to current suppliers what documentation is needed and by what date, with consequences for non-delivery.
- Build buffer inventory from compliant suppliers before transitioning off non-compliant ones.
Documentation Build-Out
Phase 2 is when documentation systems get built, not just used:
- Quality agreements executed with all Tier 1 and Tier 2 suppliers
- Chain of custody documentation collected and filed for every active ingredient lot
- COAs organized by lot number in an accessible filing system (digital or physical)
- Supplier qualification records current and accessible
Phase 3: Confirmation (Days 91–120 — September 30–October 31, 2026)
Phase 3 is about verifying that everything done in Phases 1 and 2 actually achieved what you intended — and building the buffer before November 12.
Compliance Verification
For every reformulated product:
- Obtain a new Certificate of Analysis confirming total THC per serving and per container from a DEA-registered, ISO 17025-accredited laboratory
- Verify the math: delta-9 THC + (THCA × 0.877) per container ≤ 0.4 mg
- Confirm label reflects the reformulated cannabinoid content accurately
For every supplier:
- Confirm all documentation gaps from Phase 1 are resolved
- Verify DEA registration of testing laboratory (registration extended to December 31, 2026 — confirm current status)
- Run a complete documentation file check: COA, chain of custody, GMP cert, quality agreement, allergen statement all present and current
Inventory Positioning
- Build 45–60 days of compliant inventory buffer before November 12
- Discontinue production of any SKUs that will not be compliant before November 12
- Communicate with retail partners about reformulated SKUs: new label versions, timing of transition, any product in their distribution chain that represents pre-reformulation inventory
Internal Readiness Review
- Conduct a tabletop exercise: if a regulator asked for your compliance documentation today, how long would it take to produce it? What would be missing?
- Update your regulatory inquiry response protocol
- Brief your sales and customer service teams on compliance messaging for post-November 12
The Buffer Weeks: November 1–12
The two weeks between October 31 and November 12 are for final confirmation, not emergency remediation. If you are still doing compliance work in the first week of November, you have insufficient buffer. The goal of this action plan is to be done by October 31 so that November 1–12 is a confirmation period, not a sprint.
Use this time to:
- Confirm all active ingredient lots in production are from compliant suppliers with current documentation
- Confirm no non-compliant SKUs remain in your distribution chain
- Brief retail partners and distributors on your compliance status
- File your compliance documentation in a location that is accessible if regulators or retailers make inquiries
The Day After: November 13, 2026
Compliance with the November 12 standard is not the end of the hemp regulatory journey — it is the beginning of the framework within which the industry operates going forward. FDA rulemaking signaled for 2027 will likely layer additional requirements on top of the current standard. The documentation systems, supplier relationships, and quality infrastructure you build during this sprint are the foundation for ongoing compliance, not a one-time project.
Organizations that treat November 12 as a deadline to cross, rather than as a permanent new standard to operate under, will find themselves building compliance infrastructure repeatedly instead of once.
